IL-1 blockade in autoinflammatory syndromes.
IL-1 blockade in autoinflammatory syndromes.
复制标题
DOI:
10.1146/annurev-med-061512-150641
复制
发表时间:
2014
影响因子:
10.5
通讯作者:
Goldbach-Mansky R
中科院分区:
文献类型:
--
作者:
Jesus AA;Goldbach-Mansky R
Monogenic autoinflammatory syndromes present with excessive systemic inflammation including fever, rashes, arthritis, and organ-specific inflammation and are caused by defects in single genes encoding proteins that regulate innate inflammatory pathways. Pathogenic variants in two interleukin-1 (IL-1)–regulating genes, NLRP3 and IL1RN, cause two severe and early-onset autoinflammatory syndromes, CAPS (cryopyrin associated periodic syndromes) and DIRA (deficiency of IL-1 receptor antagonist). The discovery of the mutations that cause CAPS and DIRA led to clinical and basic research that uncovered the key role of IL-1 in an extended spectrum of immune dysregulatory conditions. NLRP3 encodes cryopyrin, an intracellular “molecular sensor” that forms a multimolecular platform, the NLRP3 inflammasome, which links “danger recognition” to the activation of the proinflammatory cytokine IL-1β. The success and safety profile of drugs targeting IL-1 in the treatment of CAPS and DIRA have encouraged their wider use in other autoinflammatory syndromes including the classic hereditary periodic fever syndromes (familial Mediterranean fever, TNF receptor–associated periodic syndrome, and hyperimmunoglobulinemia D with periodic fever syndrome) and additional immune dysregulatory conditions that are not genetically well defined, including Still’s, Behcet’s, and Schnitzler diseases. The fact that the accumulation of metabolic substrates such as monosodium urate, ceramide, cholesterol, and glucose can trigger the NLRP3 inflammasome connects metabolic stress to IL-1β-mediated inflammation and provides a rationale for therapeutically targeting IL-1 in prevalent diseases such as gout, diabetes mellitus, and coronary artery disease.
登录
查看更多内容
影响因子:
27.4
作者:
Bodar, E. J.;Kuijk, L. M.;Frenkel, J.
通讯作者:
Frenkel, J.
DOI:
10.1056/nejmoa0807865
发表时间:
2009-06-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
Aksentijevich I;Masters SL;Ferguson PJ;Dancey P;Frenkel J;van Royen-Kerkhoff A;Laxer R;Tedgård U;Cowen EW;Pham TH;Booty M;Estes JD;Sandler NG;Plass N;Stone DL;Turner ML;Hill S;Butman JA;Schneider R;Babyn P;El-Shanti HI;Pope E;Barron K;Bing X;Laurence A;Lee CC;Chapelle D;Clarke GI;Ohson K;Nicholson M;Gadina M;Yang B;Korman BD;Gregersen PK;van Hagen PM;Hak AE;Huizing M;Rahman P;Douek DC;Remmers EF;Kastner DL;Goldbach-Mansky R
通讯作者:
Goldbach-Mansky R
DOI:
10.1084/jem.20102049
发表时间:
2011-03-14
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Bulua AC;Simon A;Maddipati R;Pelletier M;Park H;Kim KY;Sack MN;Kastner DL;Siegel RM
通讯作者:
Siegel RM
影响因子:
11.1
作者:
Bauernfeind, Franz;Hornung, Veit
通讯作者:
Hornung, Veit
影响因子:
3.6
作者:
Calligaris, Lorenzo;Marchetti, Federico;Tommasini, Alberto;Ventura, Alessandro
通讯作者:
Ventura, Alessandro